RecruitingNCT06739330

Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease


Sponsor

Tanta University

Enrollment

150 participants

Start Date

Dec 19, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age ≥ 18 years.
  • Both sexes.
  • Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).

Exclusion Criteria4

  • History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
  • Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
  • Viral hepatitis.
  • Pregnant women.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFibroscan

Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.


Locations(1)

Tanta University

Tanta, El-Gharbia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06739330


Related Trials